Vol 7, Supplement 4 (April 26, 2018): Translational Cancer Research


Neurological complications of anti-PD-1 antibodies: shall we be more concerned?
Kyrillus S. Shohdy, Omar Abdel-Rahman
ZATT, TDP2, and SUMO2: breaking the tie that binds TOP2 to DNA
Steven R. Hall, Kerry Brennan Goralski
Evolutionary acquired robustness and vulnerability in cancer genome: negligible negative selection in carcinogenesis
Kazuki Kumada, Jun Yasuda
Fibroblast growth factor signaling as a bypass mechanism of the androgen receptor pathway: new perspectives for castrationresistant prostate cancer
Ihsan Y. El-Sayed, Francis Vacherot, Stéphane Terry
PD-1 in cancer: Dr. Jekyll and Mr. Hyde
Marion Alcantara, Melania Tesio, Vahid Asnafi
Myc and Ras, the Bonnie and Clyde of immune evasion
Sílvia Casacuberta-Serra, Laura Soucek
Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic
Naomi Lomeli, Daniela A. Bota
The emerging landscape of lncRNAs in diabetic nephropathy
Xiaoyun He, Chibin Pu, Chunlin Ou, Suxian Zhou
A human mutated gene is guillotining spermatozoa
Jesús del Mazo, Miguel A. Brieño-Enríquez, Eduardo Larriba
Hypofractionated whole breast irradiation is cost-effective—but is that enough to change practice?
Apar Gupta, Nisha Ohri, Bruce G. Haffty
Adjuvant chemotherapy in patients with newly diagnosed non-co-deleted anaplastic gliomas—a new standard
Kelly Lauren Braun, David Marc Peereboom
Editorial: fate mapping of human glioblastoma reveals an invariant stem cell hierarchy
Sabrina P. Koh, Agadha C. Wickremesekera, Tinte Itinteang, Swee T. Tan
Duloxetine for AI-associated joint pain in breast cancer patients
Moe Tsuda, Masakazu Toi
Temozolomide—the jack of all gliomas? Reviewing the interim results of the CATNON trial for 1p/19q non-co-deleted anaplastic glioma
Mateo Ziu, Jeffrey I. Traylor
When the inhibitor is turned into stimulator: novel aspects in T cell engineering
Felicitas Rataj, Stefan Endres, Sebastian Kobold
There must be another way—disulfiram and cancer treatment: editorial on “Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4”
Hovav Nechushtan, Tamar Peretz
Disulfiram combats cancer via crippling valosin-containing protein/p97 segregase adaptor NPL4
Nan Ding, Qianzheng Zhu
How many pancreatic cysts are out there and how to best manage them?
Victor Ciofoaia, Nadim G. Haddad, Jill P. Smith
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma
Deborah Cosentini, Sandra Sigala, Elisa Saba, Elisa Roca, Alfredo Berruti
Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma
David C. Binder, Erik Ladomersky, Alicia Lenzen, Lijie Zhai, Kristen L. Lauing, Sebastian D. Otto-Meyer, Rimas V. Lukas, Derek A. Wainwright
Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer
Kazuhiro Araki, Yasuo Miyoshi
Role of enhancer activation in pancreatic cancer metastasis
Paloma Cejas, Marta Mendiola, Jaime Feliu
Circular RNA FBXW7: implication in glioma tumorigenesis
Luka Bolha, Damjan Glavač
Improving hormonal therapy: to extend, to intermit, or to readjust expectations?
Iris Noordhoek, Esther Bastiaannet, Cornelis J. H. van de Velde


This supplement was published without any sponsorship or funding.